Global Oncology Academy

Best Practices for Detecting ESR1 Mutations in Metastatic Breast Cancer

ReachMD Healthcare Image
RestartResume

Here’s how you can best utilize liquid biopsies to monitor ESR1 mutation status in patients with metastatic breast cancer.

Take Post-Survey

If you’ve already completed the activity.

  • Overview

    When treating patients with metastatic breast cancer, it’s important to repeatedly conduct liquid biopsies to look for acquired ESR1 mutations when patients progress after endocrine therapy, even if initial testing was done. That’s why Dr. Charles Turck is breaking down best practices for utilizing liquid biopsies to detect ESR1 mutations with Drs. Stephanie Graff and Pavani Chalasani. Dr. Graff is the Director of Breast Oncology at the Lifespan Cancer Institute in Providence, Rhode Island, and Dr. Chalasani is the Division Director of Hematology-Oncology at the GW Cancer Center in Washington, DC.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free